When choosing among them, factors such as glycemic efficacy, weight effects and patient preferences may take precedence over concerns about major differences in [GI] risk. She added clinicians should continue to monitor for GI symptoms, particularly early in treatment, as these events, while uncommon, remain more frequent than with some other diabetes drug classes. According to Alkabbani and colleagues, recent trials revealed that dulaglutide (Trulicity, Eli Lilly), semaglutide (Ozempic/Wegovy, Novo Nordisk) and tirzepatide (Zepbound, Eli Lilly) increased the risk for mild to serious GI adverse events like pancreatitis, constipation, nausea, vomiting and biliary disease
A variant associated with lower GLP-1 receptor expression might suggest stronger benefit from combined GLP-1 and AMPK-targeted therapies like berberine, but this should be interpreted with a qualified healthcare provider who knows your full clinical picture
Weight Loss Clinic Portland is the place to be
Referral to specialist dietitians can help individuals develop personalised nutrition strategies that promote gradual, sustainable weight loss whilst ensuring adequate nutritional intake
&srotate=0)
